CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for RegeneRx Biopharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

RegeneRx Biopharmaceuticals Inc
15245 SHADY GROVE ROAD, SUITE 470
Phone: (301) 208-9191p:301 208-9191 ROCKVILLE, MD  20850  United States Ticker: RGRXRGRX
Business Summary
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4 (TB4), for tissue and organ protection, repair, and regeneration. The Company has formulated TB4 into three distinct product candidates in clinical development: RGN-259, RGN-352 and RGN-137. RGN-259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-259 is in phase three clinical trials in the United States and EU for the treatment of neurotrophic keratitis, an orphan indication. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, organ damage associated with COVID-19, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue. It has active partnerships in four territories: North America, Europe, China and Pan Asia.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Founder, Chief Scientific Officer Allan L.Goldstein 85 1/1/1982 1/1/1982
President, Chief Executive Officer, Director J. J.Finkelstein 70 1/1/2002 1/1/1984
Director AlessandroNoseda 64 4/1/2019 4/1/2019
3 additional Officers and Directors records available in full report.

Business Names
Business Name
RegeneRx Biopharmaceut.
RGRX
RGRXD

General Information
Number of Employees: 2 (As of 12/31/2022)
Outstanding Shares: 1,496,966 (As of 10/18/2023)
Shareholders: 4,037
Stock Exchange: OTC
Federal Tax Id: 521253406
Fax Number: (301) 208-9194


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, February 1, 2025